In this interview Thomas speaks about the importance to increase awareness on CMT so that people get diagnosed rapidly (by the way the ECMTF CMT awareness campaign will take place next October); the efforts that can be made to manage CMT; the symptoms and the different types of CMT; the pharmacological treatment landscape, in particular the two investigational pharmacological agents being studied: PXT 3003 (Pharnext) and ACE-038 (Acceleron). To read the whole interview, follow the link: https://bit.ly/2LOmzrY
An in-depth interview on Charcot-Marie-Tooth disease with K. Florian P. Thomas
Published on July 30th, 2019
To read latest news
January 10th, 2020The new R-Barometer H-CARE survey on the care experience of patients with...
January 7th, 2020InFlectis BioScience Announces Successful Completion of Phase 1 Clinical Trial of...
January 7th, 2020Pharnext Announces Encouraging Data from Open-Label Phase 3 Extension Study of PXT3003...